We are live on ! Find out more
KAPA

Kairos Pharma

1.84 USD
+0.17
10.18%
At close Updated Sep 4, 4:00 PM EDT
Pre-market
After hours
1.93
+0.09
4.89%
1 day
10.18%
5 days
8.88%
1 month
-19.3%
3 months
-43.56%
6 months
-58.28%
Year to date
-63.99%
1 year
-83.04%
5 years
-89.89%
10 years
-89.89%
 

About: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.

Employees: 1

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 16.7%
Neutral 83.3%
Negative 0%
Neutral
Business Wire
15 days ago
Kairos Pharma Announces 1-for-7 Reverse Stock Split
LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a spl.
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Neutral
Business Wire
1 month ago
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma's lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Kairos Pharma's current programs with.
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Neutral
Newsfile Corp
1 month ago
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers. Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc. , is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality.
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Neutral
Business Wire
1 month ago
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca's Tagrisso®) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The data represent a pivotal milestone in Kairos Pharma's lead program: resensitizing patien.
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
Neutral
Newsfile Corp
2 months ago
Kapa Gold Announces the Results of Its 2026 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 19, 2026) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa" or the "Company") is pleased to announce the results of its annual meeting of shareholders held virtually online on June 18, 2026 (the "Meeting").
Kapa Gold Announces the Results of Its 2026 Annual General Meeting
Neutral
Business Wire
3 months ago
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: To our valued Kairos Pharma Shareholders, As we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates to our existing pipeline. We an.
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Neutral
Business Wire
3 months ago
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Leaders in Drug Resistance Development 2026 - USA award recipient. Following a merit-led research and evaluation process by GHP's expert research and judging team, based on innovation, impact, business performance and contributi.
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
Neutral
Newsfile Corp
3 months ago
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, CA May 18th and 19th, 2026.
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Neutral
Business Wire
4 months ago
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026. After the meeting materials are finalized and filed with the Securities and Exchanges Commission, such materials will be mailed to shareholders. The Company also advises its Financial Statements included in its Annual Report o.
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
Price charts implemented using Lightweight Charts™